penicillin-susceptible, erythromycin-susceptible S. pneumoniae. [7] [8] [9] [10] [11] Its activity against penicillin-intermediate, penicillin-resistant or erythromycin-resistant S. pneumoniae is not known.
The objective of this work was to characterize more fully the potency of the metabolite against penicillin-and erythromycin-resistant S. pneumoniae, and to investigate whether this metabolite has a role in the parent compound's activity against these organisms in vitro. We investigated the in vitro activity of the metabolite alone and in combination with clarithromycin against several clinical strains of penicillin-intermediate, penicillin-resistant and erythromycin-resistant S. pneumoniae. Interaction was tested by investigating combination MICs, agar dilution chequerboards and time-kill assays.
Materials and methods
The pneumococci tested included 38 clinical isolates and one ATCC control strain (S. pneumoniae 49619). These consisted of 24 penicillin-intermediate (MIC 0.1-1.0 mg/L) and 14 penicillin-resistant S. pneumoniae (MIC у 2.0 mg/L). Twenty five of these isolates were erythromycin susceptible (MIC р 0.25 mg/L) and 13 erythromycin resistant (MIC у 1 mg/L). MICs of erythromycin, azithromycin and penicillin were also determined, and erythromycin and azithromycin were included in chequerboard and time-kill testing for comparison. Clarithromycin and metabolite were obtained from Abbott Laboratories (Abbott Park, IL, USA). Erythromycin, azithromycin and penicillin V potassium were obtained from the United States Pharmacopoeia (Rockville, MD, USA).
Agar dilution MICs were determined according to the standards of the NCCLS with incubation in 5% CO 2 . Final antibiotic concentrations tested were 0.001-64 mg/L. S. pneumoniae ATCC 49619 and S. aureus ATCC 29213 were included for quality control. All procedures were performed in duplicate. MICs were determined for each agent individually and for clarithromycin and metabolite in a 2:1 and 1:1 ratio.
Isolates that were not susceptible to erythromycin (MIC у 1 mg/L) were screened for the presence of known MLS B resistance genes by polymerase chain reaction (PCR) amplification with the following gene-specific primers: erm(AM): upper primer (5Ј position 974), TCAACCAAATAAT AAAACAA, lower (3Ј position 1311), AATCCTTCTT CAACAATCAG; mef(E): upper (5Ј position 206), ATGCAGACCAAAAGCCACCAT, lower (3Ј position 439), GCCATAGACAAGACCATCGC. 12 Crude lysates of the strains were prepared and stored at 4°C until tested. One microlitre of lysate was used in a 25 L amplification reaction (PCR Supermix; Gibco-BRL, Bethesda, MD, USA). The presence of the erm(AM) and mef(E) genes was identified in 13 organisms.
Agar chequerboard testing was performed using the 25 erythromycin-susceptible and 13 erythromycin-resistant isolates by combining the parent compound and metabolite, each at concentrations of 0.001-64 mg/L. 13 Interaction between the two compounds was determined by calculating the fractional inhibitory concentration (FIC) index. 13 FIC indices were interpreted as follows: р0.5, synergy; Ͼ0.5-1, additive; Ͼ1-4, indifference; and Ͼ4, antagonism.
14 Standardized time-kill assays were performed in a CO 2 environment using 10 representative pneumococcal strains (two erythromycin resistant). The macrolides were each tested alone at simulated physiological peak serum concentrations: clarithromycin, 2.6 mg/L; metabolite, 0.8 mg/L; azithromycin, 0.4 mg/L; and erythromycin, 2.0 mg/L. [15] [16] [17] Clarithromycin and metabolite were also tested in combination. All work was performed in duplicate. There was excellent correlation between duplicate colony counts, so results presented are mean values.
Results
Metabolite alone was as potent as the parent compound against S. pneumoniae (Tables I and II The clarithromycin/metabolite combination in a 2:1 ratio was more potent than clarithromycin (having a lower MIC) for 25 strains of pneumococcus tested (19 with a decrease of one tube dilution and six with a decrease of two or more tube dilutions). The combination in a 1:1 ratio was more potent than clarithromycin alone (having a lower MIC) for 28 strains of pneumococcus tested (17 with a decrease of one tube dilution and 11 with a decrease of two tube dilutions). In five of the 13 erythromycin-resistant isolates the clarithromycin MIC was reduced by one or more tube dilutions by combination with the metabolite (Table II) .
Synergy was demonstrated against 13 strains and additive effects against 18 strains of S. pneumoniae. Against erythromycin-resistant organisms, three of eight erm(AM)-producing strains demonstrated synergy, as compared with three of five mef(E)-producing strains. Against erythromycin-susceptible isolates, seven of 25 strains demonstrated synergy, 16 additive effects and two indifference.
14-Hydroxy clarithromycin activity against S. pneumoniae
Representative time-kill curves for macrolide-resistant isolates are shown in Figures 1 and 2 . For the macrolidesusceptible isolates (data not shown), clarithromycin and its 14-hydroxy metabolite alone and in combination were bactericidal and produced colony counts below the lower limit of detection at 24 h. Against the macrolide-resistant [mef(E)], penicillin-resistant isolate (Figure 1 ), clarithromycin and the combination of parent and metabolite reduced the colony count by approximately 2 log cfu/mL at 24 h, whereas growth in the presence of all other agents resembled that of the control. For the macrolide-resistant [erm(AM)], penicillin-intermediate S. pneumoniae ( Figure  2 ), an initial decrease in colony counts was observed over the first 12 h in the presence of clarithromycin, its metabolite, the combination and erythromycin, but in all tubes there was regrowth above baseline at 24 h.
Clarithromycin and its metabolite completely eradicated seven of the 10 organisms (seven of the eight erythromycinsusceptible strains and neither of the two erythromycinresistant ones). The time required for bactericidal activity to be manifested was determined for these seven isolates. The combination of parent and metabolite was more rapidly bactericidal than clarithromycin alone in six of the seven isolates (P ϭ 0.026). Metabolite was more rapidly bactericidal than clarithromycin in five of the seven isolates, but the cumulative difference did not reach statistical significance (P ϭ 0.222).
Discussion
We speculated that clarithromycin's active metabolite, 14-hydroxy clarithromycin, may have significant activity against penicillin-and erythromycin-intermediate and 14-Hydroxy clarithromycin activity against S. pneumoniae -resistant pneumococci, and contribute to the parent drug's clinical effectiveness. There are no reports of in vitro activity of the metabolite against these pathogens. The few data describing the compound's activity against S. pneumoniae isolates suggest that its potency is equal to or greater than that of its parent compound. 7, 9 Clarithromycin and its metabolite have demonstrated synergy in combination against other bacteria, and this interaction may be responsible for the seemingly few clinical failures of this drug against S. pneumoniae strains that are not susceptible to penicillin. 8, 18, 19 In MIC testing, the MIC of clarithromycin was reduced in Ͼ70% of the isolates when clarithromycin was combined with metabolite in a serum physiological ratio. Jones et al. 18 demonstrated similar findings for the combination against Legionella spp. The results of agar chequerboard studies confirmed this interaction, as 31 of 38 isolates demonstrated synergy or additive effects. To investigate the pharmacodynamic nature of the interaction, we performed time-kill assays against a variety of penicillin-intermediate, -resistant and macrolide-resistant isolates. Simulated serum concentrations were chosen for testing to simulate bacteraemia in vivo. We chose a 2:1 ratio of parent to metabolite to allow comparison of our results with those of other investigators. 7, 18 Chu et al. 15 demonstrated that in healthy young and elderly volunteers the ratio of parent to metabolite C max and C min serum concentrations after five doses of clarithromycin (500 mg bd) ranged from 2.46:1 to 3.65:1 and from 1.92:1 to 2.28:1, respectively. One would expect that higher concentrations of these agents, as might be present in epithelial lining fluid, would produce similar or greater activity against pneumococcal strains. In all but the high-level macrolide-resistant isolate tested [I-B, erm(AM)], the clarithromycin/metabolite combination was more potent than the parent compound. In seven of the 10 time-kill assays, bactericidal activity was demonstrated for all of the macrolides. Thus, macrolides may not be effective against all pneumococcal isolates, but in vitro MICs may not be an accurate predictor of pharmacodynamic effect.
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The erm gene probably encodes high-level macrolide resistance; our work confirms that of others in this regard.
20
In time-kill testing against an erm(AM)-expressing strain, erythromycin, and clarithromycin and metabolite either alone or in combination reduced colony counts over the first 12 h of the assay. Clarithromycin alone and in combination with the metabolite produced an approximately 2 log cfu/mL reduction in the macrolide-resistant strain encoded by the mef(E) gene. Erythromycin and azithromycin appeared to have little activity against this strain. This efflux mechanism produces low-to moderate-level macrolide resistance, and organisms expressing this gene may not be uniformly affected by the macrolides.
We have demonstrated that 14-hydroxy clarithromycin has activity against S. pneumoniae in vitro and that it contributes to the activity of clarithromycin in MIC and time-kill studies. Further work on the activity of this combination against mef(E)-and erm(AM)-expressing macrolide-resistant pneumococci is warranted. This work supports the argument that the activity of active metabolites must be taken into consideration in determining the antimicrobial activity of parent drugs. 
585

